• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone.

作者信息

Liang Shih-Hsin, Yeh Su-Peng

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Rd., Dalin Township, Chiayi County, 62247, Taiwan.

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yu Der Road, Taichung, 40447, Taiwan.

出版信息

Ann Hematol. 2019 Oct;98(10):2447-2450. doi: 10.1007/s00277-019-03761-4. Epub 2019 Jul 23.

DOI:10.1007/s00277-019-03761-4
PMID:31338571
Abstract
摘要

相似文献

1
Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone.复发的多发性骨髓瘤表现为TEMPI综合征，对挽救性来那度胺和地塞米松治疗反应良好。
Ann Hematol. 2019 Oct;98(10):2447-2450. doi: 10.1007/s00277-019-03761-4. Epub 2019 Jul 23.
2
Carfilzomib weekly 20/56 mg/m , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.卡非佐米每周20/56毫克/平方米、来那度胺和地塞米松用于早期复发难治性多发性骨髓瘤。
Am J Hematol. 2019 Jan;94(1):E17-E20. doi: 10.1002/ajh.25327. Epub 2018 Nov 25.
3
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.MM-011 研究的成熟结果：脂质体多柔比星、长春新碱、地塞米松和来那度胺联合治疗复发/难治性多发性骨髓瘤，随后进行来那度胺维持治疗的 I/II 期临床试验。
Am J Hematol. 2014 Apr;89(4):349-54. doi: 10.1002/ajh.23639. Epub 2014 Feb 24.
4
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.来那度胺和地塞米松联合佩利司他治疗复发/难治性多发性骨髓瘤的疗效：一项多发性骨髓瘤研究联盟的 I 期研究。
Br J Haematol. 2012 Aug;158(4):472-80. doi: 10.1111/j.1365-2141.2012.09173.x. Epub 2012 May 29.
5
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.开放标签、随机、III期ASPIRE试验的健康相关生活质量结果：评估卡非佐米、来那度胺和地塞米松与来那度胺和地塞米松用于复发多发性骨髓瘤患者的疗效比较
J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648.
6
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.一项评估伏立诺他联合来那度胺和地塞米松治疗既往含来那度胺方案治疗耐药的多发性骨髓瘤患者的 IIb 期临床试验。
Br J Haematol. 2017 Feb;176(3):440-447. doi: 10.1111/bjh.14429. Epub 2016 Nov 18.
7
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.来那度胺和地塞米松治疗肾功能受损的多发性骨髓瘤复发患者：PrE1003，一项 PrECOG 研究。
Blood Cancer J. 2018 Aug 29;8(9):86. doi: 10.1038/s41408-018-0110-7.
8
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者：一项非干预性研究的最终结果及与关键3期临床试验的比较
Leuk Res. 2018 May;68:90-97. doi: 10.1016/j.leukres.2018.03.008. Epub 2018 Mar 14.
9
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.苯达莫司汀联合沙利度胺和地塞米松是骨髓瘤对硼替佐米和来那度胺复发和/或难治时的一种可行挽救方案。
Ann Hematol. 2015 Apr;94(4):643-9. doi: 10.1007/s00277-014-2238-2. Epub 2014 Oct 28.
10
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.

引用本文的文献

1
TEMPI syndrome: difficult to diagnose, "easy" to treat?TEMPI 综合征：诊断困难，“治疗”容易？
Ann Hematol. 2024 Sep;103(9):3787-3793. doi: 10.1007/s00277-024-05893-8. Epub 2024 Jul 30.
2
[TEMPI syndrome: 4 cases report and literature review].[TEMPI综合征：4例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):683-686. doi: 10.3760/cma.j.issn.0253-2727.2023.08.013.
3
Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment.具有临床意义的单克隆丙种球蛋白病（MGCS）：追求最佳治疗。
Front Immunol. 2022 Nov 23;13:1045002. doi: 10.3389/fimmu.2022.1045002. eCollection 2022.
4
Coexistence of TEMPI syndrome and leukocytoclastic vasculitis successfully treated with autologous stem cell transplantation.TEMPI综合征与白细胞破碎性血管炎并存，经自体干细胞移植成功治疗。
EJHaem. 2022 Oct 10;3(4):1385-1387. doi: 10.1002/jha2.561. eCollection 2022 Nov.
5
Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal.具有临床意义的单克隆丙种球蛋白病：批判性评估
Cancers (Basel). 2022 Oct 26;14(21):5247. doi: 10.3390/cancers14215247.
6
Case Report: TEMPI syndrome: Report of three cases and treatment follow-up.病例报告：TEMPI综合征：三例报告及治疗随访
Front Oncol. 2022 Aug 3;12:949647. doi: 10.3389/fonc.2022.949647. eCollection 2022.
7
TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.TEMPI 综合征：临床特征、治疗和发病机制的最新进展。
Front Endocrinol (Lausanne). 2022 May 19;13:886961. doi: 10.3389/fendo.2022.886961. eCollection 2022.
8
Ocular involvement in TEMPI syndrome.TEMPI综合征的眼部受累情况。
Am J Ophthalmol Case Rep. 2022 Apr 10;26:101534. doi: 10.1016/j.ajoc.2022.101534. eCollection 2022 Jun.
9
Diagnosis and management of monoclonal gammopathy of clinical significance.具有临床意义的单克隆丙种球蛋白病的诊断与管理
Blood Res. 2022 Apr 30;57(S1):20-26. doi: 10.5045/br.2022.2022035.
10
Cutaneous manifestations of monoclonal gammopathy.单克隆丙种球蛋白病的皮肤表现。
Blood Cancer J. 2022 Apr 11;12(4):58. doi: 10.1038/s41408-022-00661-1.